India, May 20 -- Shares of India's fourth-largest pharmaceutical company by value came into focus after a strong set of Q4 and FY26 results, with operating margins expanding sharply in the March quarter and the company's first full partial-year consolidation of BSV Limited reflecting in both topline and mix improvement. The investor presentation was filed with BSE and NSE on 19th May, 2026.

With a market capitalisation of approximately Rs. 1,06,212.47 crore as of 31st March, 2026, the shares of Mankind Pharma Limited were trading at Rs. 2,571.8 per share, up 3.18 percent from its previous close of Rs.2,492.6.The stock trades at a P/E of 53.42.

The March quarter was the cleaner of the two stories in this result. Revenue came in at Rs. 3...